SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California

John Gubatan; Steven Levitte; Tatiana Balabanis; Akshar Patel; Arpita Sharma; Aida Habtezion

doi:10.1053/j.gastro.2020.05.009

SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California

Gastroenterology. 2020 Sep;159(3):1141-1144.e2. doi: 10.1053/j.gastro.2020.05.009. Epub 2020 May 7.

Authors

John Gubatan¹, Steven Levitte², Tatiana Balabanis³, Akshar Patel³, Arpita Sharma³, Aida Habtezion³

Affiliations

¹ Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California. Electronic address: [email protected].
² Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California; Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
³ Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.

No abstract available

Keywords: ACE, angiotensin-converting enzyme; COVID-19, Coronavirus Disease 2019; IBD, inflammatory bowel disease; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.

MeSH terms

Adult
Aged
Betacoronavirus*
COVID-19
COVID-19 Testing
California
Clinical Laboratory Techniques*
Cohort Studies
Coronavirus Infections / diagnosis*
Coronavirus Infections / epidemiology*
Female
Humans
Inflammatory Bowel Diseases / complications*
Male
Middle Aged
Pandemics
Pneumonia, Viral / diagnosis*
Pneumonia, Viral / epidemiology*
Prevalence
Risk Factors
SARS-CoV-2